Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Premia Spine

SAS9: MIS Hits Primetime

The Ninth Annual Symposium for the International Society for the Advance of Spine Surgery (SAS9), held this spring in London, welcomed almost 1,700 attendees, double that of 2008, and most sessions provided a spirit of optimism despite the harsh economic environment. Minimally invasive surgery (MIS) took center stage as applications widen and techniques improve, while facet joint replacement devices and materials to simplify revisions also drew crowds.

Medical Device

Archus: Using Old Principles to Open a New Market in Spine

By focusing on an overlooked but critical element of spinal anatomy, the facet joint, Archus is applying established principles of total joint replacement to create a new opportunity in spine, while also expanding the potential opportunities in disc replacement.

Medical Device Business Strategies

Artificial Discs: Experiencing a Cooling Trend

Artificial discs are experiencing a cooling trend owing to an expected reduction in CMS reimbursement for both cervical and lumbar disc replacement. Many motion preservation companies are reaching critical regulatory milestones that will likely require a step-up in funding to conduct the large scale clinical studies needed to gain PMA approval. Today, companies in this sector are faced with the troubling task of either scaling back R&D programs to conserve cash or raising additional capital to take the next steps.

Medical Device

Artificial Discs: Where Do We Go from Here?

Artificial discs are experiencing a cooling trend owing to an expected reduction in CMS reimbursement for both cervical and lumbar disc replacement. Many motion preservation companies are reaching critical regulatory milestones that will likely require a step-up in funding to conduct the large scale clinical studies needed to gain PMA approval. Today, companies in this sector are faced with the troubling task of either scaling back R&D programs to conserve cash or raising additional capital to take the next steps. This article first appeared in the June 2008 issue of In Vivo.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Other Names / Subsidiaries
    • Impliant, Ltd.
UsernamePublicRestriction

Register